ASCO: Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

 – June 5, 2015  –– 

Isabelle Germano, MD, of The Mount Sinai Hospital talks with Medpage Today at the Annual Meeting for the American Society of Clinical Oncology. She discusses a study using a combination of Nivolumab and Ipilimumab for untreated melanoma. Of the study she says, β€œIt is quite interesting because it is finally targeting patients that have melanoma overall and not just those with a BRAF mutation.”

-Isabelle Germano, MD, Professor, Neurosurgery, Neurology, Oncological Sciences, Icahn School of Medicine at Mount Sinai

Learn more